


# LYSOSOMAL STORAGE DISORDERS

## A PRACTICAL GUIDE

Edited by Atul Mehta & Bryan Winchester



 WILEY-BLACKWELL

# Contents

Contributors

Preface

Foreword

## PART 1 General Aspects of Lysosomal Storage Diseases

CHAPTER 1 The Lysosomal System:  
Physiology and Pathology

Introduction

The greater lysosomal system

Lysosomal diseases

Concluding remarks

CHAPTER 2 Clinical Aspects and Clinical  
Diagnosis

Introduction

Clinical presentation

CHAPTER 3 Laboratory Diagnosis of  
Lysosomal Storage Diseases

Referral to specialist laboratory

Preliminary screening tests on urine or blood

[Diagnosis of lysosomal enzyme defects](#)  
[LSDs due to defects in non-enzymatic proteins](#)  
[Neuronal ceroid lipofuscinoses \(NCLs\)](#)  
[Molecular genetic testing](#)  
[Prenatal diagnosis](#)  
[Prospects](#)  
[Acknowledgements](#)

## [CHAPTER 4 Genetics of Lysosomal Storage Disorders and Counselling](#)

[Introduction](#)  
[Genes, proteins, stored substrates, clinical phenotypes and diagnosis](#)  
[Incidence and prevalence](#)  
[Populations at a high-risk](#)  
[Burden of illness](#)  
[Population screening and diagnostic methods](#)  
[Counselling issues](#)

## [CHAPTER 5 Classification of Lysosomal Storage Diseases](#)

[Basis of classification of lysosomal storage diseases](#)  
[Acknowledgements](#)

## [PART 2 The Individual Diseases](#)

### [CHAPTER 6 Gaucher Disease](#)

[A representative case history](#)

[Gaucher disease](#)

[Epidemiology](#)

[Etiology and pathogenesis: genetic basis](#)

[Clinical forms](#)

[Diagnosis](#)

[Biomarkers](#)

[Routine follow-up of patients](#)

[Enzyme replacement therapy \(ERT\) for Gaucher disease: alglucerase and imiglucerase](#)

[Dosing regimens](#)

[Malignancies](#)

[Global shortage of imiglucerase \(June 2009\)](#)

[Other treatment options: substrate reduction therapy \(SRT\)](#)

[Summary](#)

## [CHAPTER 7 Fabry Disease](#)

[Epidemiology](#)

[Genetic basis](#)

[Pathophysiology](#)

[Clinical presentation](#)

[Natural history](#)

[Laboratory diagnosis](#)

[Treatment](#)

[Treatment guidelines](#)

## [CHAPTER 8 The Gangliosidoses](#)

## CHAPTER 9 Metachromatic Leukodystrophy and Globoid Cell Leukodystrophy

MLD and GLD

Case studies

Epidemiology

Genetics

Pathophysiology

Clinical presentation

Diagnosis by MRI

Laboratory diagnosis

Treatment

Natural history studies

## CHAPTER 10 Types A and B Niemann–Pick Disease

Representative case histories

Epidemiology

Genetics

Pathophysiology

Clinical presentation

Natural history

Laboratory diagnosis

Treatment

Acknowledgements and conflicts of interest

## CHAPTER 11 Niemann–Pick Disease Type C

Case histories

[Epidemiology](#)  
[Genetic basis](#)  
[Pathophysiology](#)  
[Clinical presentation](#)  
[Natural history](#)  
[Laboratory diagnosis](#)  
[Treatment](#)

## [CHAPTER 12 The Mucopolysaccharidoses](#)

[Epidemiology](#)  
[Genetic basis](#)  
[Pathophysiology](#)  
[Clinical presentation](#)  
[Natural history](#)  
[Laboratory diagnosis](#)  
[Treatment](#)  
[Acknowledgements](#)

## [CHAPTER 13 Pompe Disease](#)

[Case histories](#)  
[Confusing nomenclature](#)  
[Epidemiology](#)  
[Genetic basis](#)  
[Pathophysiology](#)  
[Clinical presentation](#)  
[Natural history](#)  
[Enzymatic and molecular diagnosis](#)  
[Treatment](#)  
[Acknowledgment](#)

Selected literature

## CHAPTER 14 Glycoproteinoses

Epidemiology

Pathophysiology

Genetic basis

Clinical presentation

Laboratory diagnosis

Treatment

An example of glycoproteinosis:  $\alpha$ -mannosidosis

Genetic basis

Pathophysiology

Clinical presentation

Natural history

Treatment

## CHAPTER 15 Defect in Protective Protein/Cathepsin A: Galactosialidosis

Epidemiology and clinical presentation

Genetic basis

Biochemistry

Pathophysiology

Diagnosis

Mouse model

Treatment

## CHAPTER 16 Multiple Enzyme Deficiencies

## 16.1 Defects in Transport: Mucopolidosis II alpha/beta, Mucopolidosis III alpha/beta and Mucopolidosis III gamma

Case histories

Epidemiology

Genetic basis

Pathophysiology

Clinical presentation

Natural history

Laboratory diagnosis

Treatment

## 16.2 Multiple Sulfatase Deficiency

Clinical presentation

Genetic basis

Biochemistry

Pathophysiology

Diagnosis

Treatment

## CHAPTER 17 Lysosomal Membrane Defects

Introduction

Cystinosis

Conclusions

Acknowledgements

## CHAPTER 18 Neuronal Ceroid Lipofuscinoses

Typical case scenarios

Epidemiology



[Genetic basis](#)

[Pathophysiology](#)

[Natural history](#)

[Laboratory diagnosis](#)

[Treatment](#)

[Treatment guidelines](#)

[Helpful further reading and websites](#)

## [CHAPTER 19 Other Lysosomal Disorders](#)

[Introduction](#)

[Farber disease: acid ceramidase deficiency  
\(OMIM: 228000\)](#)

[Lysosomal acid lipase deficiency: Wolman Disease  
and Cholesteryl Ester Storage Disease \(OMIM:  
278000\)](#)

[Defects in equilibrative nucleoside transporter 3 -  
a new lysosomal transporter defect?](#)

[Defects in the lysosomal proteases, cathepsins](#)

[Disorders of biogenesis of lysosome-related  
organelles](#)

[Stuttering](#)

## [PART 3 Therapy and Patient Issues](#)

### [CHAPTER 20 Current Treatments](#)

[Introduction](#)

[General considerations](#)

[Specific strategies for treating lysosomal diseases](#)

[Enzyme enhancement](#)

Substrate restriction therapy (“substrate reduction therapy”).

Pharmacological chaperone therapy (also see Chapter 22).

Substrate removal

Conclusions

## CHAPTER 21 Central Nervous System Aspects, Neurodegeneration and the Blood-Brain Barrier

Introduction

CNS storage and neuropathology

Normal function of the blood-brain barrier

Therapeutic delivery across the blood-brain barrier

Development of the blood-brain barrier

Damage to the blood-brain barrier in lysosomal storage diseases

## CHAPTER 22 Emerging Treatments and Future Outcomes

Introduction

Approaches to CNS Enzyme Delivery

Alternative Enzyme Variants for CNS Targeting

Gene/Cell Based Interventions

Augmentation of mRNA Translation/Natural Enzyme Function

Indirect therapies

Combination therapies

## Conclusions

### CHAPTER 23 Newborn, High Risk and Carrier Screening for Lysosomal Storage Disorders

Introduction

Carrier screening

High risk population screening

Newborn screening

Methodological issues of screening

Considerations of screening

Conclusions

### CHAPTER 24 The Patient Perspective on Rare Diseases

Introduction

The scale of the problem

Facing the challenges

Access to treatment

A United Kingdom perspective

The current situation in the UK, 2012

A European perspective

Conclusion

## Index



---

# Lysosomal Storage Disorders

## *A Practical Guide*

EDITED BY

*Atul Mehta*

Clinical Director, Lysosomal Storage Disorders Unit  
Professor of Haematology, University College London  
Royal Free Hospital  
London, UK

*Bryan Winchester*

Emeritus Professor of Biochemistry  
UCL Institute of Child Health at Great Ormond Street Hospital  
University College London  
London, UK

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

This edition first published 2012, © 2012 by John Wiley & Sons, Ltd.

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

*Registered Office*

John Wiley & Sons, Ltd, The Atrium, Southern Gate,  
Chichester, West Sussex, PO19 8SQ, UK

*Editorial Offices*

9600 Garsington Road, Oxford, OX4 2DQ, UK  
The Atrium, Southern Gate, Chichester, West Sussex, PO19  
8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell)

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information

in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Lysosomal storage disorders : a practical guide / edited by  
Atul Mehta, Bryan Winchester.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-67087-3 (pbk. : alk. paper)

I. Mehta, Atul B. II. Winchester, Bryan.

[DNLM: 1. Lysosomal Storage Diseases. 2. Lysosomes-  
pathology. WD 205]

571.6'55-dc23

2012017385

A catalogue record for this book is available from the British  
Library.

Wiley also publishes its books in a variety of electronic  
formats. Some content that appears in print may not be  
available in electronic books.



# Contributors

## **Andrea Ballabio, MD**

Director, TIGEM (Telethon Institute of Genetics and Medicine)

Naples, Italy;

Professor, Department of Molecular and Human Genetics

Baylor College of Medicine

Houston, TX, USA;

Jan and Dan Duncan Neurological Research Institute

Texas Children's Hospital

Houston, TX, USA;

Medical Genetics

Department of Pediatrics

Federico II University

Naples, Italy

## **Michael Beck**

Children's Hospital

University of Mainz

Mainz, Germany

## **David J. Begley, BSc, PhD**

Senior Lecturer in Physiology

Kings College London

London, UK

## **Erik J. Bonten, PhD**

Department of Genetics

St. Jude Children's Research Hospital  
Memphis, TN, USA

**Thomas Braulke, PhD**

Department of Biochemistry  
Children's Hospital  
University Medical Center Hamburg-Eppendorf  
Hamburg, Germany

**T. Andrew Burrow, MD**

Assistant Professor  
The Division of Human Genetics  
University of Cincinnati Department of Pediatrics and  
Cincinnati Children's Hospital Medical Center  
Cincinnati, OH, USA

**Joe T.R. Clarke, MD, PhD**

Professor Emeritus (Pediatrics)  
University of Toronto  
Toronto, ON, Canada  
Professor d'enseignement clinique  
Centre Hospitalier Universitaire  
Sherbrooke, QC, Canada

**Jonathan D. Cooper, BSc(Hons), PhD**

Professor of Experimental Neuropathology  
Pediatric Storage Disorders Laboratory, Neuroscience  
Centre for the Cellular Basis of Behaviour  
King's Health Partners Centre for Neurodegeneration  
Research  
James Black Centre

Institute of Psychiatry  
King's College London  
London, UK

**Timothy M. Cox, MD, FMedSci**

Professor of Medicine  
University of Cambridge  
Addenbrooke's Hospital  
Cambridge, UK

**Alessandra d'Azzo, PhD**

Member and Endowed Chair  
Department of Genetics  
St. Jude Children's Research Hospital  
Memphis, TN, USA

**Robert J. Desnick, PhD, MD**

Dean for Genetic and Genomic Medicine  
Professor and Chairman Emeritus  
Department of Genetics and Genomic Sciences  
Mount Sinai School of Medicine  
New York, NY, USA

**Graciana Diez-Roux**

Telethon Institute of Genetics and Medicine  
Naples, Italy

**Deborah Elstein, PhD**

Clinical Research Coordinator  
Gaucher Clinic

Shaare Zedek Medical Center  
Jerusalem, Israel

**Volkmar Gieselmann, MD**

Professor of Biochemistry  
Institut fuer Biochemie und Molekularbiologie  
Rheinische-Friedrich-Wilhelms Universitaet  
Bonn, Germany

**Roberto Giugliani, MD, PhD**

Professor, Department of Genetics,  
Federal University of Rio Grande do Sul  
Director, WHO Collaborating Centre  
Medical Genetics Service, HCPA  
Porto Alegre, RS, Brazil

**Gregory A. Grabowski, MD**

The A. Graeme Mitchell Chair in Human Genetics  
Professor and Director, Human Genetics  
Cincinnati Children's Hospital Medical Center  
University of Cincinnati  
Cincinnati, OH, USA

**Carla E.M. Hollak, MD, PhD**

Internist, Professor of Inherited Metabolic Diseases in Adults  
Department of Endocrinology and Metabolism  
Academic Medical Center  
Amsterdam, The Netherlands

**John J. Hopwood, AM, FAA, PhD**

Lysosomal Diseases Research Unit  
SA Pathology at Women's and Children's Hospital  
North Adelaide, SA, Australia

**Alastair Kent**

Director  
Genetic Alliance UK  
London, UK

**Ingeborg Krägeloh-Mann, MD**

Professor of Pediatrics  
Director, Pediatric Neurology and Developmental Medicine  
University Children's Hospital  
Tübingen, Germany

**Christine Lavery, MBE**

Chief Executive  
Society for Mucopolysaccharide Diseases  
Amersham, Buckinghamshire, UK

**Gabor E. Linthorst, MD, PhD**

Internist-Endocrinologist  
Department of Internal Medicine, Endocrinology and  
Metabolism  
Academic Medical Center  
Amsterdam, The Netherlands

**Dag Malm, MD, PhD**

The Tromsø Centre of Internal Medicine (TIS)  
Tromsø, Norway

**Jeremy Manuel, OBE**

Chairman  
European Gaucher Alliance  
Dursley, Gloucestershire, UK

**Atul Mehta**

Clinical Director  
Lysosomal Storage Disorders Unit  
Department of Haematology, University College London  
Royal Free Hospital  
London, UK

**Matthew C. Micsenyi**

The Dominick P. Purpura Department of Neuroscience  
Albert Einstein College of Medicine  
Bronx, NY, USA

**Øivind Nilssen**

Professor  
Department of Clinical Medicine-Medical Genetics  
University of Tromsø; Department of Medical Genetics  
University Hospital of North-Norway  
Tromsø, Norway

**Marc C. Patterson, MD, FRACP**

Chair, Division of Child and Adolescent Neurology  
Professor of Neurology, Pediatrics and Medical Genetics  
Mayo Clinic  
Rochester, MN, USA

**Sandra Pohl, PhD**

Department of Biochemistry  
Children's Hospital  
University Medical Center Hamburg-Eppendorf  
Hamburg, Germany

**Annick Raas-Rothschild, MD**

Associate Professor of Genetics  
Department of Human Genetics and Metabolic Diseases  
Hadassah Hebrew University Medical Center  
Ein Kerem  
Jerusalem, Israel

**Uma Ramaswami, MBBS, MSc, MD, FRCPCH**

Consultant Metabolic Paediatrician  
The Willink Biochemical Genetics Unit  
Genetic Medicine  
St Mary's Hospital  
Manchester, UK

**Arnold J.J. Reuser**

Department of Clinical Genetics  
Center for Lysosomal and Metabolic Diseases  
Erasmus MC University Medical Center  
Rotterdam, The Netherlands

**Paul Saftig, PhD**

Biochemical Institute

Christian-Albrechts-University Kiel  
Kiel, Germany

**Maurizo Scarpa**

Department of Paediatrics  
University of Padova  
Padova, Italy

**Edward H. Schuchman, PhD**

Genetic Disease Foundation - Francis Crick Professor  
Vice Chairman for Research  
Department of Genetics and Genomic Sciences  
Mount Sinai School of Medicine  
New York, NY, USA

**Michael Schwake, PhD**

Biochemical Institute  
Christian-Albrechts-University Kiel  
Kiel, Germany

**Hilde Monica F. Riise Stensland, DrSc**

Senior Scientist  
Department of Medical Genetics  
University Hospital of North-Norway  
Tromsø, Norway

**Ans T. van der Ploeg**

Department of Pediatrics  
Center for Lysosomal and Metabolic Diseases



Erasmus MC University Medical Center  
Rotterdam, The Netherlands

**Marie T. Vanier, MD, PhD**

Director of Research (Emeritus)  
Institut National de la Santé et de la Recherche Médicale  
and Hospices Civils de Lyon  
Lyon, France

**Steven U. Walkley, DVM, PhD**

Director, Rose F. Kennedy Intellectual and Developmental  
Disabilities Research Center  
Professor of Neuroscience, Pathology and Neurology  
Albert Einstein College of Medicine  
Bronx, NY, USA

**Melissa P. Wasserstein**

Department of Genetics and Genomic Sciences  
Mount Sinai School of Medicine  
New York, NY, USA

**David A. Wenger, PhD**

Professor of Neurology  
Thomas Jefferson University, Jefferson Medical College  
Philadelphia, PA, USA

**Ruth E. Williams**

Department of Paediatric Neurology  
Evelina Childrens Hospital

Guy's and St Thomas' NHS Foundation Trust  
London, UK

**Bryan Winchester**

Biochemistry Research Group  
UCL Institute of Child Health at Great Ormond Street  
Hospital  
University College London  
London, UK

**J. Edmond Wraith, MBChB, FRCPCH**

Professor of Paediatric Metabolic Medicine  
Manchester Academic Health Sciences Centre;  
Willink Biochemical Genetics Unit  
Royal Manchester Children's Hospital  
Manchester, UK

**Ari Zimran, MD**

Gaucher Clinic  
Shaare Zedek Medical Center  
The Hebrew University - Hadassah Medical School  
Jerusalem, Israel

# Preface

The concept of a lysosomal storage disorder is now almost 50 years old – an appropriate time, we feel, for a new review of the subject.

The term lysosome was coined by Christian de Duve [1], the discoverer of this organelle, to reflect its role as the major intracellular site for the enzymatic ‘lysis’ of macromolecules so that they may be recycled. The concept of a lysosomal storage disorder was first proposed by H G Hers [2], following the discovery that one of the glycogen storage diseases (Pompe disease, acid maltase deficiency) was due to deficiency of a lysosomal enzyme. The concept of ‘cross-correction’, formulated by Elizabeth Neufeld [3] and her group after the discovery that co-cultured fibroblasts derived from two patients with different lysosomal storage disorders mutually corrected each other, led to the notion of ‘enzyme replacement therapy’ (ERT). Roscoe Brady not only discovered the enzymatic basis for Gaucher disease and Fabry disease but also pioneered ERT for humans [4,5].

The last two decades, however, have seen a huge expansion in research in this area which has substantially extended our understanding of both the scientific and the clinical basis of lysosomal storage disorders [6]. Thus, at a scientific level it is now very well recognised that lysosomes are part of an endosomal/lysosomal network which plays a critical role in a whole range of cellular processes including the recycling of membrane and other organelles, the turnover of molecules and ingested matter through endocytosis and phagocytosis, and an emerging role in apoptosis and autophagy. At a clinical level successful treatments have been employed which reduce substrate

accumulation or promote substrate degradation but it is increasingly recognised that the protean multi-system manifestations of these conditions result from pathologic processes over and above simple lysosomal storage and damage.

This book is the fruit of an ambitious project which aims to review both the scientific and the clinical aspects of lysosomal storage disorders. We perceive a need for an accessible volume giving an up to date overview of the subject. Even when effective treatments are available, there remains an urgent need to highlight awareness of the diseases so that early and appropriate treatment may be sought [7]. Furthermore, in a rapidly changing world, there is a real need to improve access to expensive treatments. The first section of the book reviews current understanding of the physiology and pathophysiology of lysosomal storage disorders and we again attempt to classify the conditions. The second part of the book reviews individual diseases, and gives perspectives from patients and experts looking towards future therapeutic directions. The book is aimed at a wide audience including scientists, clinicians, health care workers and administrators, those working in the pharmaceutical industry, patients and their organisations.

We are highly indebted to Christine Lavery, the Founder and Chief Executive of the Society for Mucopolysaccharidosis Diseases (MPS Society, UK). Christine has been an integral part of the project from the very beginning, a partner during its production and a driver towards its completion. The extremely high regard in which she is held internationally has allowed us to assemble a glittering array of distinguished contemporary scientists and clinicians working in this area. Furthermore, all contributors and the editors have donated their royalties to the MPS society, which is dedicated to promote research into these diseases and to the support of patients and families who

suffer from them. We are also grateful to Shire HGT which has made the project possible through an unrestricted educational grant given to the MPS Society. The Editors and contributors take full responsibility for the contents of the book and confirm that Shire HGT, the MPS Society and Wiley-Blackwell have not had any role in influencing the content of the work.

We would also like to thank Elisabeth Dodds, Production Manager, Nick Godwin and Rob Blundell at Wiley-Blackwell who have helped us at every stage of the project. Our distinguished contributors have made time in their busy schedules to prepare and revise their contributions and we thank them for their patience, timeliness, clarity and charity in delivering their chapters to us.

We would each like to acknowledge some, of our many, academic mentors. For Atul this has to be Lucio Luzzatto, a clinician and scientist who guided his early academic career, emphasising the need for meticulous and reflective observation and record. Atul would also like to thank Victor Hoffbrand, who has provided invaluable encouragement during his career as a clinician, academic – and as a writer. Bryan would like to thank Don Robinson for introducing him to lysosomal storage diseases and giving him his first job, and Bob Jolly, who taught him the importance of linking pathology and biochemistry through the study of animal models. Finally, we would both like to thank our respective wives and families for their continuing forbearance and support.

Atul Mehta  
Bryan Winchester

## References

1 de Duve C, Pressman B, Gianetto R, Wattiaux R, Appelmanns F. Tissue fractionation studies: Intracellular

distribution patterns of enzymes in rat-liver tissue. *Biochem J* 1955;**64**:604-617.

2 Hers HG. Alpha glucosidase deficiency in generalised glycogen storage disease (Pompe Disease). *Biochem J* 1963;**86**:11-16.

3 Fratantoni JC, Hall CW, Neufeld EF. The defect in Hurler and Hunter Syndromes II deficiency of specific factor involved in mucopolysaccharide degradation. *Proc Nat Acad.Sci USA* 1969; **64**:360-366.

4 Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. *Proc Natl Acad Sci USA*. 1990;**87**:1913-6.

5 Brady RO. Enzyme replacement therapy for lysosomal diseases *Annu Rev Med* 2006; **57**: 283-296.

6 Cox TM, Cachon-Gonzales MB. The cellular pathology of lysosomal diseases. *J Pathol* 2012; **226**:241-254.

7 D'Aco K, Underhill L, Rangachani L *et al*. Diagnosis and treatment trends in mucopolysaccharidosis I; findings from the MPS I registry. *Eur J Pediatr* 2012: Advance online publication.